Anaphylaxis Risk Following Xolair Administration

Immediate Anaphylaxis Risk

Anaphylaxis occurs in approximately 0.09-0.2% of patients, with most reactions occurring within the first 2 hours after Xolair injection, according to the American Academy of Allergy, Asthma, and Immunology 1, 2
Analysis of 41 anaphylactic events showed that 61% (22/36) occurred within the first 2 hours after one of the first three doses, with 16 reactions occurring within 30 minutes, 7 reactions between 30-60 minutes, and 5 reactions between 1-2 hours, as reported by the American College of Allergy, Asthma, and Immunology 1, 2, 3, 4

Five anaphylactic reactions occurred between 2-12 hours post-injection, with delayed reactions including tongue swelling, lingual angioedema, increased asthma symptoms with urticaria, and shortness of breath with watery, itchy eyes and throat closing sensation, as noted by the American Academy of Allergy, Asthma, and Immunology 1, 2, 3, 5
Three anaphylactic reactions occurred beyond 12 hours, with reactions documented up to 4 days after administration, according to the American College of Allergy, Asthma, and Immunology 1, 2

Patients must be observed for 2 hours after the first 3 injections and 30 minutes after subsequent injections, as this captures 75% of anaphylactic reactions, as recommended by the American Academy of Allergy, Asthma, and Immunology 3, 4
All patients must carry an epinephrine autoinjector for the 24 hours following injection and be educated that reactions can occur up to 4 days later, as advised by the American College of Allergy, Asthma, and Immunology 6, 7

The monitoring protocol recommends observing patients for 2 hours after each of the first three omalizumab injections and for 30 minutes after all subsequent injections; this observation window captures approximately 75 % of anaphylactic reactions. 8

Before every omalizumab injection, clinicians should evaluate the patient’s current health status and any recent changes, record vital signs, and assess lung function using peak expiratory flow (PEF) or FEV₁ measurements. 8

All patients initiating omalizumab therapy must receive an informed‑consent discussion regarding anaphylaxis risk, be prescribed an epinephrine autoinjector before starting therapy, and receive training on proper autoinjector use prior to the first dose. 8

Anaphylaxis risk: Approximately 0.09 %–0.2 % of individuals receiving omalizumab experience anaphylaxis, with reactions reported after the first dose and even beyond one year of continuous therapy. This estimate is derived from clinical data reported by the American Academy of Allergy, Asthma & Immunology. 9

IgE binding: Omalizumab is a recombinant humanized monoclonal antibody that selectively binds free circulating IgE, thereby neutralizing its activity. (Evidence level: basic science/clinical pharmacology). 10
Down‑regulation of IgE receptors: By binding free IgE, omalizumab reduces expression of IgE receptors on mast cells, basophils, and dendritic cells, which prevents activation of the allergic cascade. (Evidence level: mechanistic study). 11